Search for content, post, videos
Advertisement

Oasmia appoints new CEO

Francois Martelet

The Board of Oasmia Pharmaceutical has appointed Francois Martelet as the new CEO.

Martelet has extensive international experience of leading pharmaceutical companies. He replaces Sven Rohmann, who has been acting CEO during a crucial transition period. Rohmann remains in his position as Board member and will continue to play an active role in the company’s commercialization strategy going forward.

Three CEO positions in the last 12 years

Francois Martelet is an experienced Pharma executive with a proven track record of shaping companies and turning around underperforming units. He has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive roles at senior level at Roche, Eli Lilly, Novartis and MSD. He has been based in six countries in Europe (including Sweden) and in the US. Francois Martelet is a French Medical Doctor, with a Masters Degree in Business. He speaks four languages, among them Swedish. Martelet will take up his position on March 15, 2020.

“We have been searching for an executive with vast international experience of commercializing pharmaceutical companies, with a proven track record in oncology, with a solid network within the medical community and also who has demonstrated to be a good leader. Francois Martelet fits excellently to our needs and we look forward to having him onboard. Sven Rohmann will continue in his Board position and will actively play an important role going forward. We are very grateful and happy with the head start that Sven has given Oasmia in laying out our new strategy, commercializing Apealea and connecting with the medical world,” says Jörgen Olsson, Chairman of the Board.

“Oasmia is a very interesting company in an exciting phase. The Board has sorted out some of the question marks of the past and has laid out a solid strategy to commercialize and also successfully concluded the rights issue in December. Now it is time to execute on the business plan, transforming the company, which is exactly the kind of work that really thrills me. I am excited to start and move back to Sweden where I lived many years ago,” says Francois Martelet.

Advertisement